Loading clinical trials...

Determining the Mechanisms of Loss of CAR T Cell Persistence | Clinical Trials | Clareo Health

RECRUITING

Determining the Mechanisms of Loss of CAR T Cell Persistence

NCT05809284•University College, London

Summary

A prospective observational study of pediatric and young adult acute lymphoblastic leukaemia (ALL) patients treated with CD19 chimeric antigen receptor T-cells (CAR-T cells). The study will examine changes in CAR-T persistence over time and causal factors.

Eligibility

Age

0 - 25 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Children and young adults (age 25 years or younger) with relapsed/refractory ALL who are planned to receive licensed CD19-targeted CAR-T cell treatment (Tisagenlecleucel)
•2. Written informed consent

Exclusion Criteria

•1. Patients receiving an alternate CD19-directed CAR T-cell product on a clinical trial
•2. Any reason that in the opinion of the investigator, patients won't be able to adhere to the protocol

Locations (3)

Great Ormond Street Hospital

London, United Kingdom

University College London Hospital

London, United Kingdom

Royal Manchester Children's Hospital

Manchester, United Kingdom

Key Dates

Start Date

October 18, 2023

Primary Completion Date

December 1, 2025

Completion Date

December 1, 2025

Last Updated

May 23, 2024

Enrollment

ESTIMATED participants

Conditions

Acute Lymphoblastic Leukemia With Failed RemissionAcute Lymphoblastic Leukemia Not Having Achieved RemissionAcute Lymphoblastic Leukemia, PediatricAcute Lymphoblastic Leukemia, AdultAcute Lymphoblastic Leukemia, in Relapse

Contacts

CARPERS Trial Manager

CONTACT

442031084189 ctc.carpers@ucl.ac.uk

Venetoclax Basket Trial for High Risk Hematologic Malignancies

NCT05292664

Myelodysplastic Syndromes, de NovoMyelodysplastic Syndromes, Secondary+9 more

View study

RECRUITINGPHASE1

A Phase I Dose Finding Study of MB-CART2219.1

NCT07108868

LymphomaCLL+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 23, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Determining the Mechanisms of Loss of CAR T Cell Persistence

Inclusion Criteria

Exclusion Criteria

Venetoclax Basket Trial for High Risk Hematologic Malignancies

A Phase I Dose Finding Study of MB-CART2219.1

Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL

Virtual Reality During Lumbar Punctures in Acute Lymphoblastic Leukemia

Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.